Abcuro
Alex Martin currently serves as the Chief Executive Officer at Abcuro, Inc. since October 2022 and has held multiple leadership roles across several biopharmaceutical companies. In addition to the CEO position, Alex is Chairman of the Board at VERALOX Therapeutics and serves as a Director at ESSA Pharmaceuticals. Previous roles include CEO of Palladio Biosciences, CEO of Realm Therapeutics, and Board Director at RASNA THERAPEUTICS LIMITED. Alex's extensive experience in the industry is complemented by an MBA from Harvard Business School and a BA in Political Science and Government from Cornell University.
This person is not in any teams
This person is not in any offices
Abcuro
2 followers
Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1). The company is advancing ABC008, a first-in-class anti-KLRG1 antibody designed to deplete cytotoxic T cells that attack healthy muscle tissue in patients with inclusion body myositis (IBM), into clinical studies.